Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2022 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will...
March 01, 2022 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen...
February 24, 2022 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates

Galafold® Revenue Growth of 17% YoY to $306M in 2021 Galafold Global Sales Growing at Double-Digits (15-20%) with $350M-$365M in 2022 U.S. and EU Regulatory Filings Under Review and Launch...
February 10, 2022 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022

PHILADELPHIA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022...
February 07, 2022 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022

PHILADELPHIA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
January 10, 2022 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance

Full-Year 2021 Galafold® Revenue of ~$306M, Representing 17% YoY Growth Expect Double-Digit Growth (15-20%) of 2022 Galafold Revenue with $350M-$365M in Global Sales U.S. and EU Regulatory Reviews...
January 05, 2022 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference, being held...
December 03, 2021 07:00 ET | Source: Amicus Therapeutics, Inc.

European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease

PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA)...
November 24, 2021 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference

PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th...
November 22, 2021 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of...